CagriSema
CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. The therapy combines two complementary mechanisms in a single weekly subcutaneous injection, achieving approximately 20% weight loss over 68 weeks in clinical trials — superior to semaglutide alone. It is in phase 3 clinical development (REDEFINE program) with FDA response pending for 2026.
Last updated:: 13/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Under review
EMA (Europe)
Under review
Mechanism of Action
CagriSema combines two peptides with complementary mechanisms. Semaglutide activates the GLP-1 receptor, stimulating insulin secretion, suppressing glucagon, and reducing appetite via hypothalamic satiety centers. Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. Amylin delays gastric emptying, suppresses glucagon secretion, and activates brain regions different from GLP-1 to promote satiety. The combination of both mechanisms — GLP-1 acting predominantly in the hypothalamus and amylin in the area postrema — creates a synergistic effect on appetite reduction, resulting in significantly greater weight loss than either component alone.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Obesidade / controle de peso
Subcutânea (SC)Titulação gradual de ambos os componentes
Dose-alvo do estudo REDEFINE-1
Combinação cagrilintida (análogo de amilina) + semaglutida (GLP-1) em injeção única semanal. Perda de peso ~20% em 68 semanas. Novo Nordisk. FDA pending 2026.
Benefits
Superior weight loss (~20%)
ProvenIn REDEFINE studies, participants lost approximately 20% of body weight over 68 weeks — superior to semaglutide 2.4 mg alone (~16%). The combination of mechanisms explains the additional efficacy.
View studySynergistic dual mechanism
ProvenThe amylin + GLP-1 combination acts on complementary neural satiety pathways. Cagrilintide adds appetite suppression via the area postrema, while semaglutide acts on the hypothalamus, generating an additive effect.
Glycemic control
Under researchStudies in patients with type 2 diabetes show robust HbA1c reduction. Amylin complements the GLP-1 action on glucose metabolism, with additional postprandial glycemia reduction.
Potential in NASH/hepatic steatosis
Under researchThe substantial weight loss (~20%) suggests significant benefits in non-alcoholic hepatic steatosis. Specific studies for NASH are being planned.
Risks and Side Effects
Nausea
Moderate(35-45% of patients)Most frequent side effect, especially during titration. The combination of two peptides may intensify gastrointestinal symptoms early in treatment. Gradual titration is essential.
Injection site reactions
Low(10-15% of patients)Redness, swelling, or mild pain at the application site. Generally transient and self-limiting. Injection site rotation is recommended.
Risk of pancreatitis
High(Rare (<1%))Class risk of GLP-1 agonists and amylin analogs. Rare but serious cases of acute pancreatitis have been reported. Discontinue immediately if severe persistent abdominal pain occurs. Contraindicated in patients with a history of pancreatitis.
Internet vs. Science
What people say online compared to the actual scientific evidence.
CagriSema is the best weight loss drug in the world
Partially trueWhat they claim
With 20% weight loss, CagriSema surpasses all other available treatments.
Actual evidence
CagriSema did demonstrate ~20% weight loss, surpassing semaglutide alone (~16%). However, retatrutide (triple agonist) achieved ~24% in phase 2 studies. Moreover, CagriSema has not yet been approved — the results are from controlled clinical trials. Comparing different studies has limitations.
It's safer than Ozempic because it uses two drugs at lower doses
FalseWhat they claim
Because it combines two drugs, each at a lower dose, the side effects are reduced.
Actual evidence
Not exactly. The semaglutide in CagriSema is used at the same 2.4 mg dose as Wegovy, with the addition of cagrilintide. Gastrointestinal effects (nausea, vomiting) tend to be similar or slightly more frequent than semaglutide alone. The overall safety profile is comparable.
CagriSema is already available at clinics in Brazil
FalseWhat they claim
Some weight loss clinics already offer the compounded cagrilintide + semaglutide combination.
Actual evidence
CagriSema has NOT been approved by any regulatory agency (FDA, ANVISA, EMA). Cagrilintide alone also has no approval. Any offer of 'CagriSema' or a similar combination is illegal and unregulated. The components require specific manufacturing conditions that cannot be replicated at compounding pharmacies.
CagriSema replaces bariatric surgery
Partially trueWhat they claim
With 20% weight loss, bariatric surgery is no longer necessary.
Actual evidence
Bariatric surgery results in 25-35% sustained weight loss over decades, plus diabetes remission in 60-80% of cases. CagriSema (~20%) approaches but is still inferior, and the effects depend on continuous use. For class III obesity (BMI > 40) or multiple comorbidities, surgery may remain the more effective option. The decision should be individualized with a physician.
| Claim | O que dizem | Evidência real | Verdict |
|---|---|---|---|
| CagriSema is the best weight loss drug in the world | With 20% weight loss, CagriSema surpasses all other available treatments. | CagriSema did demonstrate ~20% weight loss, surpassing semaglutide alone (~16%). However, retatrutide (triple agonist) achieved ~24% in phase 2 studies. Moreover, CagriSema has not yet been approved — the results are from controlled clinical trials. Comparing different studies has limitations. | Partially true |
| It's safer than Ozempic because it uses two drugs at lower doses | Because it combines two drugs, each at a lower dose, the side effects are reduced. | Not exactly. The semaglutide in CagriSema is used at the same 2.4 mg dose as Wegovy, with the addition of cagrilintide. Gastrointestinal effects (nausea, vomiting) tend to be similar or slightly more frequent than semaglutide alone. The overall safety profile is comparable. | False |
| CagriSema is already available at clinics in Brazil | Some weight loss clinics already offer the compounded cagrilintide + semaglutide combination. | CagriSema has NOT been approved by any regulatory agency (FDA, ANVISA, EMA). Cagrilintide alone also has no approval. Any offer of 'CagriSema' or a similar combination is illegal and unregulated. The components require specific manufacturing conditions that cannot be replicated at compounding pharmacies. | False |
| CagriSema replaces bariatric surgery | With 20% weight loss, bariatric surgery is no longer necessary. | Bariatric surgery results in 25-35% sustained weight loss over decades, plus diabetes remission in 60-80% of cases. CagriSema (~20%) approaches but is still inferior, and the effects depend on continuous use. For class III obesity (BMI > 40) or multiple comorbidities, surgery may remain the more effective option. The decision should be individualized with a physician. | Partially true |
Studies and References (3)
Wadden TA, Hollander P, Klein S, et al. — New England Journal of Medicine (2025) — n=3417
Perda de peso de aproximadamente 20% em 68 semanas em adultos com obesidade (IMC ≥30). Perfil de segurança consistente com estudos anteriores. Resultados que suportam a submissão regulatória ao FDA.
PubMedFrias JP, Deenadayalan S, Erichsen L, et al. — The Lancet (2024) — n=92
Combinação de cagrilintida + semaglutida resultou em perda de peso de até 15,6% em 32 semanas, superior à semaglutida isolada. Demonstrou sinergismo entre os mecanismos de amilina e GLP-1. Base para o programa fase 3 REDEFINE.
PubMedLau DCW, Erichsen L, Francisco-Ziller N, et al. — Diabetes, Obesity and Metabolism (2023) — n=92
Caracterização farmacocinética da cagrilintida isolada. Meia-vida longa permitindo administração semanal. Redução de peso dose-dependente de até 4,4 kg em 26 semanas como monoterapia. Perfil de segurança aceitável que fundamentou a combinação com semaglutida.
PubMedFrequently Asked Questions
What exactly is CagriSema?
CagriSema is a fixed-dose combination of two peptides in a single weekly injection: cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist, the same active ingredient in Ozempic/Wegovy). Novo Nordisk is developing the product as an evolution of standalone semaglutide.
What is the difference between CagriSema and Amycretin?
They are different products from Novo Nordisk. CagriSema combines two separate peptides (cagrilintide + semaglutide) in one injection. Amycretin is a single molecule that integrates GLP-1 and amylin activity in the same peptide — it is at an earlier stage of development. Both exploit the amylin + GLP-1 synergy but with distinct molecular approaches.
When will CagriSema be approved?
Novo Nordisk submitted CagriSema to the FDA with a response expected in the second half of 2026. If approved in the US, the ANVISA submission will likely follow within 6-12 months, with Brazilian approval estimated for 2028-2029.
Is it better than Wegovy (semaglutide)?
In clinical trials, yes: CagriSema (~20% weight loss) outperformed semaglutide alone (~16%). The dual mechanism (amylin + GLP-1) explains the superior efficacy. However, CagriSema may have higher costs and is not yet commercially available. For many patients, semaglutide alone may be sufficient.
Can I use cagrilintide separately along with my Ozempic?
No. Cagrilintide (amylin analog) is not commercially available as a standalone product. The CagriSema combination was developed with specific proportions and careful titration. Combining medications on your own is dangerous and can cause severe hypoglycemia or other serious adverse effects. Never combine medications without medical guidance.
Important notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
Not Yet Available
This compound is still experimental and has not been approved for use. Sign up to be notified when it becomes available.